ORMP ORAMED PHARMACEUTICALS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1176309 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY435.3%
TTM EPS YoY412.5%
Revenue 3-yr CAGR-11.9%
Net income 3-yr CAGR—
Margins
Gross margin0.7%
Operating margin-754.4%
Net margin3,202.5%
FCF margin-457.7%
EBITDA margin-748.4%
Returns
ROE37.0%
ROA33.2%
ROIC (approx.)-10.4%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.5%
Debt / equity0.00x
Current ratio6.98x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.14x
Accruals ratio37.9%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-08-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.00M | — | $1.34M | $2.70M | $2.70M |
| Cost of revenue | $1.99M | — | — | — | — |
| Gross profit | $13,000 | — | — | — | — |
| R&D expense | $6.38M | $6.32M | $8.97M | $27.64M | $20.99M |
| SG&A expense | $8.72M | $6.46M | $8.43M | $13.81M | $5.94M |
| Operating income | -$15.09M | -$12.78M | -$15.77M | -$40.60M | -$24.22M |
| Interest expense | — | $853,000 | $2.04M | — | — |
| Pretax income | $75.32M | -$15.92M | $5.09M | -$37.66M | $5.31M |
| Income tax | $11.31M | $3.18M | — | $100,000 | — |
| Net income | $64.05M | -$19.06M | $5.09M | -$36.56M | -$22.99M |
| EBITDA | -$14.97M | -$12.59M | -$15.57M | -$40.54M | -$24.15M |
| EPS (basic) | 1.53 | -0.48 | 0.14 | -0.94 | 0.78 |
| EPS (diluted) | 1.50 | -0.48 | 0.14 | -0.94 | 0.78 |
| Dividends declared per share | 0.25 | — | — | — | — |
| Weighted avg. shares (diluted) | 42.42M | 40.85M | 40.57M | 39.00M | 28.47M |
| Balance sheet | |||||
| Cash & equivalents | $45.95M | $54.42M | $9.05M | $40.46M | $77.25M |
| Short-term investments | $5.42M | $3.44M | $57.71M | $3.74M | $5.85M |
| Current assets | $133.27M | $143.22M | $162.58M | $157.11M | $95.34M |
| PP&E, net | $586,000 | $698,000 | $873,000 | $815,000 | $397,000 |
| Total assets | $230.86M | $155.28M | $220.55M | $161.64M | $128.00M |
| Current liabilities | $19.09M | $5.68M | $53.21M | $5.75M | $6.68M |
| Short-term debt | — | — | $51.01M | — | — |
| Long-term debt | — | — | — | $25,000 | $12.54M |
| Total debt | — | — | — | $25,000 | $12.54M |
| Total liabilities | $31.12M | $9.93M | $57.66M | $10.49M | $11.48M |
| Shareholders' equity | $199.74M | $146.26M | $163.82M | $151.81M | $115.77M |
| Net debt | — | — | — | -$40.44M | -$64.70M |
| Shares outstanding | 39.28M | 39.92M | 40.34M | 39.56M | 35.29M |
| Cash flow statement | |||||
| Operating cash flow | -$9.14M | -$8.41M | -$10.29M | -$27.92M | -$21.18M |
| Capital expenditure | $9,000 | $18,000 | $254,000 | $496,000 | $375,000 |
| Free cash flow | -$9.15M | -$8.43M | -$10.55M | -$28.41M | -$21.56M |
| Investing cash flow | $5.44M | $105.82M | -$73.04M | $30.21M | -$23.76M |
| Financing cash flow | -$4.74M | -$52.04M | $51.98M | $10.78M | $102.89M |
| Depreciation & amortization | $121,000 | $193,000 | $196,000 | $58,000 | $77,000 |
| Stock-based compensation | $5.99M | $4.05M | $4.21M | $11.51M | $2.69M |
| Share buybacks | $4.74M | $2.48M | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.